Changes after 12 years of follow-up severe asthma patients cohort: higher obstruction and comorbidities, but significant better quality of life
Carregando...
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
TAYLOR & FRANCIS LTD
Autores
Citação
JOURNAL OF ASTHMA, v.60, n.2, p.298-303, 2023
Resumo
Background The Brazilian Cohort of Asthma Sao Paulo (BRASASP) had a well-characterized severe asthmatic in Brazil, with 12 years of follow-up under standard treatment. Methods Sequential assessment of patients with uncontrolled asthma from BRASASP cohort was carried out with 12 years of follow-up, performing exams and comparing with previous measurements. Results 50 from the 60 initial patients were reevaluated. Twelve years later, FEV1 and the FEV1/FVC ratio have significantly decreased, with a rate of loss of lung function of 11.8 and 14%, respectively, and worsening in small airway parameters such as RV/TLC. BMI, The Asthma Control Test (ACT) and Asthma Control Questionnaire (ACQ) scores haven't changed. However, exacerbations decreased by 56%. Mean daily inhaled corticosteroid use was similar over time, but daily oral corticosteroid use decreased, in addition to a significant reduction in induced sputum eosinophilic and neutrophilic profile and serum IgE. Rhinitis, sinusitis, and GERD were the main comorbidities. In quality of life according to respiratory questionnaire SGRQ, total score showed a huge improvement (62% of patients). Conclusions There was significant decrease in FEV1 and FEV1/FVC. Data of pulmonary functional small airway characteristics show globally affected airways. Although higher doses of medications, patients were still uncontrolled, but with reduction of exacerbations, daily use of oral corticosteroid, less eosinophils and neutrophils in induced sputum and lower levels of IgE. Improvement in quality of life in 62% of patients.
Palavras-chave
Asthma, asthma control, airway inflammation, airway obstruction, quality of life
Referências
- [Anonymous], 2020, GINA GLOBAL INITIATI
- Athanazio R, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0314-1
- Bel EH, 2011, THORAX, V66, P910, DOI 10.1136/thx.2010.153643
- Chipps BE, 2018, J ALLERGY CLIN IMMUN, V141, P1590, DOI 10.1016/j.jaci.2017.07.014
- de Carvalho-Pinto RM, 2012, RESP MED, V106, P47, DOI 10.1016/j.rmed.2011.08.013
- Israel E, 2017, NEW ENGL J MED, V377, P965, DOI 10.1056/NEJMra1608969
- Postma DS, 2019, LANCET RESP MED, V7, P402, DOI 10.1016/S2213-2600(19)30049-9
- Ray A, 2016, J CLIN INVEST, V126, P2394, DOI 10.1172/JCI84144